• Acasti blames phase 3 lipid-lowering flop on placebo response

    10 days ago - By Fierce Biotech

    A phase 3 trial of Acasti Pharma's omega-3 drug CaPre has missed its primary endpoint, denting its hopes of challenging Amarin's Vascepa for the hypertriglyceridemia market. Yet, Acasti still thinks its drug has a chance, pointing to the reduction in triglyceride levels in the placebo group to explain the failure.
    Read more ...